Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
G9kkAuBthDPXvVUA
